SK279526B6 - Farmaceutický prostriedok na riadenie vylučovania - Google Patents

Farmaceutický prostriedok na riadenie vylučovania Download PDF

Info

Publication number
SK279526B6
SK279526B6 SK4036-91A SK403691A SK279526B6 SK 279526 B6 SK279526 B6 SK 279526B6 SK 403691 A SK403691 A SK 403691A SK 279526 B6 SK279526 B6 SK 279526B6
Authority
SK
Slovakia
Prior art keywords
ranitidine
pharmaceutical composition
indications
secretion
relating
Prior art date
Application number
SK4036-91A
Other languages
English (en)
Slovak (sk)
Inventor
John M. Padfield
Ian K. Winterborn
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10542680&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK279526(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of SK279526B6 publication Critical patent/SK279526B6/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
SK4036-91A 1983-05-13 1991-12-23 Farmaceutický prostriedok na riadenie vylučovania SK279526B6 (sk)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB838313217A GB8313217D0 (en) 1983-05-13 1983-05-13 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
SK279526B6 true SK279526B6 (sk) 1998-12-02

Family

ID=10542680

Family Applications (1)

Application Number Title Priority Date Filing Date
SK4036-91A SK279526B6 (sk) 1983-05-13 1991-12-23 Farmaceutický prostriedok na riadenie vylučovania

Country Status (20)

Country Link
US (1) US4585790A (ja)
JP (1) JPH0639378B2 (ja)
AU (1) AU568647B2 (ja)
BE (1) BE899635A (ja)
CA (1) CA1216240A (ja)
CH (1) CH662272A5 (ja)
CZ (1) CZ281598B6 (ja)
DE (1) DE3417606C2 (ja)
DK (1) DK165663B (ja)
FR (1) FR2547727B1 (ja)
GB (2) GB8313217D0 (ja)
IE (1) IE57397B1 (ja)
IL (1) IL71813A (ja)
IT (1) IT1179367B (ja)
NL (1) NL194429C (ja)
NZ (1) NZ208127A (ja)
PH (1) PH20574A (ja)
SE (1) SE459898B (ja)
SK (1) SK279526B6 (ja)
ZA (1) ZA843584B (ja)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8629781D0 (en) * 1986-12-12 1987-01-21 Glaxo Group Ltd Pharmaceutical compositions
IL90245A (en) * 1988-05-11 1994-04-12 Glaxo Group Ltd Resin adsorption containing ranitidine together with synthetic resin replaces cations, its preparation and pharmaceutical preparations containing it
US5219563A (en) * 1988-05-11 1993-06-15 Glaxo Group Limited Drug adsorbates
FR2633181B1 (fr) * 1988-06-24 1992-01-10 Glaxo Lab Sa Composition pharmaceutique a base de ranitidine et son procede de preparation
GB8927503D0 (en) * 1989-12-04 1990-02-07 Kronem Systems Inc Enzyme-amplified lanthanide chelate luminescence
US5169864A (en) * 1991-11-15 1992-12-08 Baxter International Inc. Unbuffered premixed ranitidine formulation
US5294433A (en) * 1992-04-15 1994-03-15 The Procter & Gamble Company Use of H-2 antagonists for treatment of gingivitis
WO1995010274A1 (en) * 1993-10-14 1995-04-20 F.H. Faulding & Co. Limited Aqueous pharmaceutical composition
US5407687A (en) * 1994-02-22 1995-04-18 Glaxo Inc. Ranitidine solid dosage form
IL112779A (en) * 1994-03-01 1999-11-30 Gergely Gerhard Granular product or tablet containing an efferescent system and an active pharmaceutical substance and its preparation
US5538737A (en) * 1994-11-30 1996-07-23 Applied Analytical Industries, Inc. Oral compositions of H2 -antagonists
US5650421A (en) * 1995-03-31 1997-07-22 Baxter International Inc. Premixed famotidine formulation
US5976578A (en) * 1996-10-10 1999-11-02 Mcneil-Ppc, Inc. Liquid antacid compositions
US5728401A (en) * 1997-04-16 1998-03-17 Ranbaxy Laboratories, Ltd. Effervescent ranitidine formulations
GB9715423D0 (en) * 1997-07-23 1997-09-24 Glaxo Group Ltd Aqueous compositions
US20070072828A1 (en) * 1998-07-24 2007-03-29 Yoo Seo H Bile preparations for colorectal disorders
US7772220B2 (en) * 2004-10-15 2010-08-10 Seo Hong Yoo Methods and compositions for reducing toxicity of a pharmaceutical compound
US7303768B2 (en) * 1998-07-24 2007-12-04 Seo Hong Yoo Preparation of aqueous clear solution dosage forms with bile acids
KR100848344B1 (ko) * 2000-02-04 2008-07-25 유서홍 담즙산 함유 청정 수용액 제형의 제조
KR100412290B1 (ko) * 2001-11-27 2003-12-31 주식회사 동구제약 라니티딘 함유 현탁제 조성물 및 그의 제조방법
WO2003055483A1 (fr) * 2001-12-27 2003-07-10 Terumo Kabushiki Kaisha Solution d'injection de famotidine
JP2006008696A (ja) * 2003-03-20 2006-01-12 Mitsubishi Pharma Corp アルギニンアミド類を含有する医薬製剤
US7145125B2 (en) * 2003-06-23 2006-12-05 Advanced Optical Technologies, Llc Integrating chamber cone light using LED sources
US20050036977A1 (en) * 2003-08-11 2005-02-17 Dilip Gole Taste-masked resinate and preparation thereof
EP1579862A1 (en) 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
US8980894B2 (en) 2004-03-25 2015-03-17 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
DE602005019582D1 (de) * 2004-08-30 2010-04-08 Seo Hong Yoo Nervenschutzwirkung von aufgelöster udca bei einem fokalen ischämischen modell
CA2584184A1 (en) * 2004-10-15 2006-04-27 Seo Hong Yoo Methods and compositions for reducing toxicity of a pharmaceutical compound
DE602005025391D1 (de) * 2004-11-01 2011-01-27 Seo Hong Yoo Verfahren und zusammensetzungen zur verringerung der neurodegeneration bei amyotrophischer lateralsklerose
US20060100271A1 (en) * 2004-11-08 2006-05-11 Keith Whitehead Stabilized aqueous ranitidine compositions
JP2006271748A (ja) * 2005-03-30 2006-10-12 Taiyo Yakuhin Kogyo Kk 変質しない注射剤包装
WO2007022105A2 (en) * 2005-08-12 2007-02-22 Rubicon Research Pvt. Ltd. Stable pharmaceutical compositions, processes for making the same, and methods of their use
WO2008039792A1 (en) * 2006-09-25 2008-04-03 Scidose Llc Stable pharmaceutical compositions of preserved formulation of ranitidine, process for making the same, and methods of their use
EP1920785A1 (en) 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising a complex of pimobendan and cyclodextrin
ES2924478T3 (es) 2012-03-15 2022-10-07 Boehringer Ingelheim Vetmedica Gmbh Formulación de comprimidos farmacéuticos para el sector médico veterinario, método de producción y uso de los mismos
CN113181110A (zh) 2013-07-19 2021-07-30 勃林格殷格翰动物保健有限公司 含有防腐的醚化的环糊精衍生物的液体水性药物组合物
WO2015082389A1 (en) 2013-12-04 2015-06-11 Boehringer Ingelheim Vetmedica Gmbh Improved pharmaceutical compositions of pimobendan
US10537570B2 (en) 2016-04-06 2020-01-21 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3626054A (en) * 1967-10-25 1971-12-07 Bard Hamilton Co Inc Lupus erythematosus skin test
GB1565966A (en) * 1976-08-04 1980-04-23 Allen & Hanburys Ltd Aminoalkyl furan derivatives
US4203909A (en) * 1978-09-26 1980-05-20 Bristol-Myers Company Furan compounds
DE3108753A1 (de) * 1981-03-07 1982-09-16 Degussa Ag, 6000 Frankfurt Neue substituierte alkyl-phenylsulfonylguanidine miteinem heterocyclischen rest

Also Published As

Publication number Publication date
NL194429C (nl) 2002-04-04
IL71813A (en) 1988-03-31
NL194429B (nl) 2001-12-03
DK237884A (da) 1984-11-14
AU2792984A (en) 1984-11-15
JPS59219225A (ja) 1984-12-10
DE3417606C2 (de) 1996-03-14
GB8313217D0 (en) 1983-06-22
JPH0639378B2 (ja) 1994-05-25
SE459898B (sv) 1989-08-21
FR2547727B1 (fr) 1988-02-26
BE899635A (fr) 1984-11-12
US4585790A (en) 1986-04-29
IT1179367B (it) 1987-09-16
NL8401524A (nl) 1984-12-03
DK237884D0 (da) 1984-05-11
GB8412108D0 (en) 1984-06-20
IT8448182A0 (it) 1984-05-11
CZ281598B6 (cs) 1996-11-13
PH20574A (en) 1987-02-18
GB2142820A (en) 1985-01-30
ZA843584B (en) 1985-12-24
AU568647B2 (en) 1988-01-07
CS403691A3 (en) 1992-08-12
IE57397B1 (en) 1992-08-26
CH662272A5 (fr) 1987-09-30
SE8402560L (sv) 1984-11-14
DK165663B (da) 1993-01-04
IE841179L (en) 1984-11-13
CA1216240A (en) 1987-01-06
GB2142820B (en) 1987-01-14
IL71813A0 (en) 1984-09-30
FR2547727A1 (fr) 1984-12-28
DE3417606A1 (de) 1984-11-15
NZ208127A (en) 1987-05-29
SE8402560D0 (sv) 1984-05-11

Similar Documents

Publication Publication Date Title
SK279526B6 (sk) Farmaceutický prostriedok na riadenie vylučovania
US6706255B2 (en) Liquid pharmaceutical compositions comprising thyroid hormones
IE62894B1 (en) Medicaments
US20090048344A1 (en) Pharmaceutical composition comprising 5-methyl-2-2' (chloro-6'-fluoroanilino phe nylacetic acid
US5068249A (en) Aqueous ranitidine compositions stabilized with ethanol
US7094414B2 (en) Famotidine injections
EA012463B1 (ru) Фармацевтическая композиция, содержащая производные пиперазина
ES2215856T3 (es) Solucion de sal monosodica tetrahidrato de n-(o-(p-pivaloiloxibenceno-sulfonilamino)benzoil)glicina y medicamento que contiene esta solucion.
WO1995010274A1 (en) Aqueous pharmaceutical composition
US6265449B1 (en) Aqueous compositions comprising ranitidine and LCMT sucrose
US6149893A (en) Pharmaceutical compositions containing calcitonin in a spray dosing feeder for intranasal administration
ES2684594B1 (es) Solución acuosa de ranitidina exenta de etanol
US20080287543A1 (en) Pharmaceutical composition comprising 5-methyl-2 (2'-chloro-6'-fluoroanillino) phen ylacetic acid
JPH0478612B2 (ja)
US4882356A (en) Stable injectable antiemetic compositions
EP0396169A2 (en) Pharmaceutical composition for topical ophthalmic use having improved local tolerability
CA2425031A1 (en) Pharmaceutical compositions